Cargando…
Phospho-eIF2α Level Is Important for Determining Abilities of BACE1 Reduction to Rescue Cholinergic Neurodegeneration and Memory Defects in 5XFAD Mice
β-Site APP-cleaving enzyme 1 (BACE1) initiates amyloid-β (Aβ) generation and thus represents a prime therapeutic target in treating Alzheimer's disease (AD). Notably, increasing evidence indicates that BACE1 levels become elevated in AD brains as disease progresses; however, it remains unclear...
Autores principales: | Devi, Latha, Ohno, Masuo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944882/ https://www.ncbi.nlm.nih.gov/pubmed/20886088 http://dx.doi.org/10.1371/journal.pone.0012974 |
Ejemplares similares
-
A combination Alzheimer’s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice
por: Devi, Latha, et al.
Publicado: (2015) -
Deletion of the eIF2α Kinase GCN2 Fails to Rescue the Memory Decline Associated with Alzheimer’s Disease
por: Devi, Latha, et al.
Publicado: (2013) -
Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level
por: Sadleir, Katherine R, et al.
Publicado: (2015) -
TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice
por: Devi, L, et al.
Publicado: (2015) -
Roles of eIF2α kinases in the pathogenesis of Alzheimer’s disease
por: Ohno, Masuo
Publicado: (2014)